["Surgery only" is not enough: potential of multimodal therapy in urothelial bladder carcinoma].

Clicks: 157
ID: 276114
2022
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Radical cystectomy is the standard treatment for muscle invasive bladder cancer. Using perioperative cisplatin-based chemotherapy, 5‑year overall survival rates are 5% higher with neoadjuvant chemotherapy compared to local therapy alone. New multimodal concepts have been developed to improve oncologic efficacy and to reduce treatment-related morbidity. Perioperative use of checkpoint inhibitors aims at improving efficacy, while bladder-preserving concepts try to avoid cystectomy in good responders. This article reviews new developments in radioimmunotherapy and perioperative combination therapies as well as bladder-preserving concepts like trimodal bladder therapy.
Reference Key
schmid2022surgeryurologie Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Schmid, S C;Lewerich, J;Retz, M;Rödel, Claus;
Journal Urologie (Heidelberg, Germany)
Year 2022
DOI
10.1007/s00120-022-01963-9
URL
Keywords
checkpoint inhibitors programmed cell death ligand 1 immune-modulating therapy perioperative treatment radioimmunotherapy

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.